Lancet HIV :重组腺病毒PG9-HIV疫苗的安全性研究

2019-03-20 MedSci MedSci原创

重组腺病毒HIV疫苗是安全的,但需要进一步考察PG9基因载体类型

PG9基因可表达一种广泛中和抗HIV抗体,近日研究人员考察了重组腺病毒(AAV) 载体疫苗rAAV1-PG9DP的安全性和耐受性。

研究在英国开展,18-45岁未感染艾滋病的健康男性志愿者参与,随机接受4×1012、4×1013、8×1013以及1.2×1014载体基因疫苗。对志愿者随访48周,主要目标是评估安全性和耐受性。次要目的是评估PG9在血清中的表达和相关的HIV中和活性。

21名志愿者参与并完成了48周随访。注射后不良反应一般为轻度或中度,不需要干预治疗。未发生不良事件或严重不良事件。研究人员采用HIV中和法检测了4名志愿者的血清中PG9,并对4名志愿者的肌肉活检标本进行了RT-PCR检测。ELISA法未在血清中检测到PG9。高剂量组10名志愿者中存在PG9抗药物抗体,同时检测到抗AAV1抗体和AAV1特异性T细胞反应。

研究认为,重组腺病毒HIV疫苗是安全的,但需要进一步考察PG9基因载体类型。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1755537, encodeId=3b4f1e5553748, content=<a href='/topic/show?id=312314133d7' target=_blank style='color:#2F92EE;'>#PG9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14133, encryptionId=312314133d7, topicName=PG9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff1436938457, createdName=风铃833, createdTime=Tue Nov 19 16:26:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829990, encodeId=bef1182999020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jul 19 13:26:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687224, encodeId=edb1168e224ef, content=<a href='/topic/show?id=6a5b9604106' target=_blank style='color:#2F92EE;'>#重组腺病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96041, encryptionId=6a5b9604106, topicName=重组腺病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ddd28353190, createdName=ms7514935887898259, createdTime=Tue Feb 11 20:26:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479695, encodeId=25fa14e9695e3, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Fri Mar 22 11:26:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363299, encodeId=4e2636329908, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Mar 21 10:23:26 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
    2019-11-19 风铃833
  2. [GetPortalCommentsPageByObjectIdResponse(id=1755537, encodeId=3b4f1e5553748, content=<a href='/topic/show?id=312314133d7' target=_blank style='color:#2F92EE;'>#PG9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14133, encryptionId=312314133d7, topicName=PG9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff1436938457, createdName=风铃833, createdTime=Tue Nov 19 16:26:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829990, encodeId=bef1182999020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jul 19 13:26:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687224, encodeId=edb1168e224ef, content=<a href='/topic/show?id=6a5b9604106' target=_blank style='color:#2F92EE;'>#重组腺病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96041, encryptionId=6a5b9604106, topicName=重组腺病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ddd28353190, createdName=ms7514935887898259, createdTime=Tue Feb 11 20:26:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479695, encodeId=25fa14e9695e3, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Fri Mar 22 11:26:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363299, encodeId=4e2636329908, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Mar 21 10:23:26 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
    2019-07-19 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1755537, encodeId=3b4f1e5553748, content=<a href='/topic/show?id=312314133d7' target=_blank style='color:#2F92EE;'>#PG9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14133, encryptionId=312314133d7, topicName=PG9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff1436938457, createdName=风铃833, createdTime=Tue Nov 19 16:26:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829990, encodeId=bef1182999020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jul 19 13:26:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687224, encodeId=edb1168e224ef, content=<a href='/topic/show?id=6a5b9604106' target=_blank style='color:#2F92EE;'>#重组腺病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96041, encryptionId=6a5b9604106, topicName=重组腺病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ddd28353190, createdName=ms7514935887898259, createdTime=Tue Feb 11 20:26:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479695, encodeId=25fa14e9695e3, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Fri Mar 22 11:26:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363299, encodeId=4e2636329908, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Mar 21 10:23:26 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1755537, encodeId=3b4f1e5553748, content=<a href='/topic/show?id=312314133d7' target=_blank style='color:#2F92EE;'>#PG9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14133, encryptionId=312314133d7, topicName=PG9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff1436938457, createdName=风铃833, createdTime=Tue Nov 19 16:26:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829990, encodeId=bef1182999020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jul 19 13:26:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687224, encodeId=edb1168e224ef, content=<a href='/topic/show?id=6a5b9604106' target=_blank style='color:#2F92EE;'>#重组腺病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96041, encryptionId=6a5b9604106, topicName=重组腺病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ddd28353190, createdName=ms7514935887898259, createdTime=Tue Feb 11 20:26:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479695, encodeId=25fa14e9695e3, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Fri Mar 22 11:26:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363299, encodeId=4e2636329908, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Mar 21 10:23:26 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1755537, encodeId=3b4f1e5553748, content=<a href='/topic/show?id=312314133d7' target=_blank style='color:#2F92EE;'>#PG9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14133, encryptionId=312314133d7, topicName=PG9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff1436938457, createdName=风铃833, createdTime=Tue Nov 19 16:26:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829990, encodeId=bef1182999020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jul 19 13:26:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687224, encodeId=edb1168e224ef, content=<a href='/topic/show?id=6a5b9604106' target=_blank style='color:#2F92EE;'>#重组腺病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96041, encryptionId=6a5b9604106, topicName=重组腺病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ddd28353190, createdName=ms7514935887898259, createdTime=Tue Feb 11 20:26:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479695, encodeId=25fa14e9695e3, content=<a href='/topic/show?id=c22089214a' target=_blank style='color:#2F92EE;'>#HIV疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8921, encryptionId=c22089214a, topicName=HIV疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1c7566889, createdName=ms306040998833292, createdTime=Fri Mar 22 11:26:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363299, encodeId=4e2636329908, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Mar 21 10:23:26 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
    2019-03-21 1dd8a7c5m95(暂无匿称)

    好文章,点赞啦!认真学习,谢谢分享给广大同好!

    0

相关资讯

联合用药治疗HIV和利什曼病共感染

内脏利什曼病与人类免疫缺陷病毒(HIV)共感染已经是一个日益严重的问题。这种类型的共感染需要特殊的疾病管理。目前,世界卫生组织推荐AmBisome单药治疗。然而,研究人员现已表明,AmBisome和米替福新的联合治疗更有效。

JAMA Oncol:HIV感染的晚期肿瘤患者可以使用免疫检查点抑制剂吗?

艾滋病又称为获得性免疫缺陷综合征(AIDS),人类免疫缺陷病毒(HIV)主要攻击人体的免疫系统。随着高活性抗病毒治疗药物的问世, HIV感染者死于AIDS相关疾病的几率越来越低,但是由于免疫系统的缺陷这部分患者各类疾病的易感性更高,包括肿瘤。免疫检查点抑制剂已经在多个瘤种、大量患者中取得较好的疗效,但其是否适用于HIV感染的晚期肿瘤患者呢?近期发布在JAMA Oncology杂志的一项荟萃分析,回

ViiV Healthcare和荷兰Radboud大学合作寻找HIV药物新靶标

ViiV Healthcare宣布与荷兰Radboud大学医疗中心合作,以寻找艾滋病毒的新药物目标。ViiV将为该中心提供专门资金,以提高人类功能基因组学项目(HFGP)在HIV疾病领域的探索。

Clin Infect Dis:HIV诊断后抗逆转录病毒治疗宜早不宜迟

2019年1月,中国、美国和加拿大学者在《Clin Infect Dis》发表了抗逆转录病毒治疗(ART)时机的全国队列研究:中国2011~2015年治疗退出和病毒学失败。

HIV如何感染了上百万中国人

2018年11月23日,国家卫健委就召开新闻发布会,截止2018年度,我国存活艾滋病感染大约在125万,预估新发感染者每年8万例左右,从1985年中国境内发现第一例HIV感染者病例,究竟是如何扩散到百万人感染的呢?

Hepatology:与单纯HCV感染者相比,HIV/HCV感染的肝硬化患者不再具有更高的肝癌或晚期肝病风险

HIV感染被普遍认为是HCV患者肝病加重的一个危险因素。然而,由于cART具有更好的疗效和安全性,使丙型肝炎患者获得治疗的机会增加,这种情况是否仍然存在尚不清楚。